It is noteworthy that the efficacy of this combined treatment is independent on BRAF mutational status of melanoma cells since it prevented tumour progression with the same efficiency in melanomas lacking activating mutations in BRAF as well as in melanoma tumours harbouring the BRAF(V600E) which is the most frequent mutation in human melanoma101. This evidence concerns the gene BRAF and neoplasm.